The present invention relates to the preparation field of azoxystrobin, and discloses a preparation method for a compound represented by formula (I). The method comprises the following steps: (1) a compound represented by formula (II) is hydrolyzed in a solvent under acidic conditions to obtain a compound represented by formula (III); and (2) the compound represented by formula (III) is reacted with a base and a methylating agent to obtain the compound represented by formula (I); in the formula, R.sub.3 is hydrogen or C.sub.1-C.sub.4 alkyl, and R.sub.4 is C.sub.1-C.sub.4 alkyl. The process for preparing azoxystrobin of the present invention not only successfully replaces trimethyl orthoformate and reduces the raw material cost, but also has high total reaction yield, and is suitable for industrial large-scale production. Experiments have proven that the yield of the prepared azoxystrobin can reach 95%. ##STR00001##

The present disclosure is concerned with 2-pyrimidone compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

This invention relates to pyrimidine derivatives, to compositions comprising the pyrimidine derivatives, to methods of making and using these compositions, and to the use of the pyrimidine derivatives as adjuvants, particularly for agrochemical use. In particular, the present invention relates to compositions comprising the pyrimidine derivatives selected from emulsifiable concentrates (EC), emulsions in water (EW), suspensions of particles in water (SC), soluble liquids (SL), capsule suspensions (CS), suspensions of particles with an emulsion (SE), dispersion concentrates (DC), suspensions of particles in oil (OD), water dispersible granules (WG), soluble granules (SG) and wettable powders (WP).

This invention relates to pyrimidine derivatives, to compositions comprising the pyrimidine derivatives, to methods of making and using these compositions, and to the use of the pyrimidine derivatives as adjuvants, particularly for agrochemical use. In particular, the present invention relates to compositions comprising the pyrimidine derivatives selected from emulsifiable concentrates (EC), emulsions in water (EW), suspensions of particles in water (SC), soluble liquids (SL), capsule suspensions (CS), suspensions of particles with an emulsion (SE), dispersion concentrates (DC), suspensions of particles in oil (OD), water dispersible granules (WG), soluble granules (SG) and wettable powders (WP).

Disulphide compounds of Formula (I) where Y is sulphuryl or sulphinyl Z is phenyl or substituted phenyl and the other variables are as defined in the claims; pharmaceutical compositions comprising these compounds and methods for making these compounds. These compounds are useful in therapeutic methods for treating microbial infection, inflammation and reducing the formation of blood clots and have non-therapeutic use as antimicrobial agents, anti-inflammatory agents and as anti-thrombotic agents.

##STR00001##

The invention relates to compositions and methods for inhibiting Krüppel-like Factor 10 (KLF10) for modulation of T regulatory cells and cancer immunotherapy.

The invention relates to compositions and methods for inhibiting Krüppel-like Factor 10 (KLF10) for modulation of T regulatory cells and cancer immunotherapy.

The present disclosure is directed to pyrimidone derivatives of Formula I and their use for selectively killing HIV infected GAG-POL expressing cells without concomitant cytotoxicity to HIV nave cells, and for the treatment or prophylaxis of infection by HIV, or for the treatment, prophylaxis or delay in the onset or progression of AIDS or AIDS Related Complex (ARC).

##STR00001##

Disclosed herein are substituted phenyl compounds of formula I as defined herein that may be utilized as inhibitors of the interaction between the subunits of hyperpolarization-activated cyclic-nucleotide gated (HCN) channels, such as HCN1, and an auxiliary subunit of HCN channels which is the tetratricopeptide repeat-containing Rab8b-interacting protein (TRIP8b). The disclosed compounds may be used in pharmaceutical compositions and methods for treating neurological diseases and disorders such as depression, and in particular Major Depressive Disorder (MDD).

Disclosed herein are substituted phenyl compounds of formula I as defined herein that may be utilized as inhibitors of the interaction between the subunits of hyperpolarization-activated cyclic-nucleotide gated (HCN) channels, such as HCN1, and an auxiliary subunit of HCN channels which is the tetratricopeptide repeat-containing Rab8b-interacting protein (TRIP8b). The disclosed compounds may be used in pharmaceutical compositions and methods for treating neurological diseases and disorders such as depression, and in particular Major Depressive Disorder (MDD).